Request Trial
gas-mask-biohazard
1 April 2013BiotechJaap Mannaerts

Biotech threats in the SPC system

At the time the supplementary protection certificates (SPC) regulation was draft ed, the legislator was well aware of the risk of SPCs becoming an instrument in ‘evergreening’ tactics—the ways in which pharmaceutical patent owners use the law and related regulatory processes to extend their IP rights.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotech
China-origin biotech assets and the hidden question of IP ownership
27 August 2026   As China-origin biotech assets flood the market, licensing deals are booming. Yet, the real strategic battle isn't just about the science—it’s about who controls the underlying IP, says Paul Calvo of Sterne Kessler
Biotech
10x Genomics dealt major blow in sequencing fight
20 August 2026   Three disputed sequencing patents took the spotlight as the Federal Circuit weighed challenges to a trio of PTAB rulings.
Biotech
Europe’s missing biotech bridge: Why IP ownership matters more than capital access
17 August 2026   Europe’s biotechnology challenge is not only whether it can fund innovation. It is whether it can continue to originate and control the foundational IP positions from which future biotech value is created. Paul Calvo of Sterne Kessler explains.


Editor's picks

The buyers' wishlist: What makes a life sciences deal stack up?
Regulation & Industry
The buyers' wishlist: What makes a life sciences deal stack up?
25 August 2026

Editor's picks

Regulation & Industry
The buyers' wishlist: What makes a life sciences deal stack up?
25 August 2026
Regulation & Industry
Where Big Pharma is betting big in the M&A boom
29 July 2026
Regulation & Industry
Buying the brains: Why is Big Pharma shopping for innovation?
27 July 2026
Regulation & Industry
Why is 2026 already a record year for M&A activity?
17 July 2026
Biotech
Sanofi launches mRNA vaccine lawsuits at Moderna and Pfizer
15 July 2026
Pharma
What’s at stake in Australia’s biggest pharma patent appeal in years?
1 July 2026

More features

FDA targets faster generic approvals in drive to slash drug prices
China-origin biotech assets and the hidden question of IP ownership
The buyers' wishlist: What makes a life sciences deal stack up?
Stris & Maher opens new Dallas office with partner hires
10x Genomics dealt major blow in sequencing fight
Europe’s missing biotech bridge: Why IP ownership matters more than capital access
The ‘Triple Point’ professional: Why patent success requires science, law, and technology
The UPC plugs another gap in its procedural rulebook